Emphysema Treatment Market Size & Share 2025 – 2034

Emphysema Treatment Market Size

The global emphysema treatment market size was valued at around USD 4.7 billion in 2024 and is estimated to grow at 4.7% CAGR from 2025 to 2034. Emphysema is a chronic lung condition in which the alveoli (air sacs) in the lungs deteriorate, impairing oxygen exchange and leading to breathing difficulties. Treatment for emphysema involves medical, surgical, and lifestyle interventions that aim to manage symptoms and slow disease progression. While the condition is incurable, treatment focuses on alleviating breathing problems, preventing complications, and improving lung function to enhance daily living.

As a key component of chronic obstructive pulmonary disease (COPD), emphysema is becoming increasingly prevalent worldwide due to factors such as smoking, aging populations, and exposure to air pollution. For example, the Forum of International Respiratory Societies reports that COPD affects approximately 200 million people globally, which represents 4% of the world’s population, and causes 3.2 million deaths annually. COPD is the third leading cause of death worldwide, underscoring the urgent need for effective treatment solutions.
 

Moreover, the growing prevalence of emphysema, especially in developed countries, is driving the demand for treatment. For instance, the American Lung Association states that over 3 million people in the U.S. have been diagnosed with emphysema, highlighting a large patient population in need of care. Additionally, the increasing number of smokers is further emphasizing the need for effective emphysema treatments. According to the Foundation for a Smoke-Free World, 4.6% of India’s population were smokers in 2021, revealing a significant market potential for emphysema treatments in regions with high smoking rates. This expanding global disease burden emphasizes the need for advanced therapeutic solutions and presents promising opportunities in emerging markets.
 

Emphysema Treatment Market Trends

• Bronchoscopic lung volume reduction (BLVR) procedures using endobronchial valves and coils are emerging as important treatment options. For example, the National Institutes of Health (NIH) reports that the number of BLVR procedures increased significantly from 153 in 2019 to 295 in 2020, doubling in just one year.
   
• These minimally invasive procedures offer effective symptom management while reducing recovery time and hospital stays compared to traditional surgical methods. The growing adoption of BLVR procedures reflects a shift towards less invasive treatment options for emphysema management.
   
• Furthermore, the development of oxygen therapy devices, portable ventilators, and inhalation delivery systems is enhancing treatment outcomes and improving patient comfort. For instance, a July 2023 article published by the National Library of Medicine states that over 1.5 million adults in the U.S. rely on supplemental oxygen, underscoring the importance of these medical devices.
   
• The healthcare industry's shift toward home-based care has led to an increase in the adoption of wearable and home-use oxygen therapy devices. This trend in home oxygen therapy is transforming the delivery of respiratory care services.
   

Emphysema Treatment Market Analysis

Based on treatment type, the market is segmented into medications, surgical interventions, and oxygen therapy. The medications segment dominated the market with the largest revenue share of 62.6% in 2024.
 

• The rising number of patients diagnosed with COPD, particularly emphysema, is driving the demand for effective treatment medications. Factors such as smoking, aging populations, and environmental pollutants contribute to the increase in diagnoses.
   
• For example, the American Lung Association reports that in 2022, 11.7 million people in the U.S., or 4.6% of adults, were diagnosed with COPD, which includes chronic bronchitis and emphysema. This highlights a significant need for improved treatment solutions.
   
• Additionally, research and development within the pharmaceutical industry are yielding more effective and targeted therapies. Advancements in drug formulations and delivery systems, such as bronchodilators, which were valued at USD 30.7 billion in 2023, are improving patient adherence and treatment outcomes.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on type, the emphysema treatment market is segmented into centriacinar, panacinar, and paraseptal. The centriacinar segment dominated the market with the largest revenue of USD 2.7 billion in 2024.
 

• The increasing prevalence of COPD across various populations is driving the demand for centriacinar emphysema treatment options, with smoking remaining a key risk factor. According to 2023 statistics from the Centers for Disease Control and Prevention, there were 791,000 emergency department visits where COPD was the primary diagnosis in the U.S., indicating a large patient population in need of treatment.
   
• Furthermore, public health campaigns and smoking cessation programs are contributing to market growth by helping prevent the progression of centriacinar emphysema in COPD populations. The World Health Organization reports that, as of 2023, tobacco smoking was responsible for more than 70% of COPD cases in high-income countries, underscoring the importance of anti-smoking initiatives in reducing risk factors for centriacinar emphysema.
   

Based on end use, the emphysema treatment market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and home care settings. The hospitals segment dominated the market with the largest revenue of USD 2.2 billion in 2024.
 

• Advanced treatment options, including new drug therapies and surgical techniques (such as lung volume reduction surgery, endobronchial valves, and lung transplantation), often require a hospital setting for proper monitoring and care. As a result, the increasing demand for these advanced treatment options is driving hospital-based emphysema treatments.
   
• Additionally, hospitals are adopting integrated care models that coordinate services across various healthcare levels, providing comprehensive emphysema treatments.
   

The U.S. emphysema treatment markets is projected to grow significantly, reaching USD 3.2 billion by 2034.
 

• The growing elderly population in the U.S. faces an increased risk of respiratory diseases, leading to higher demand for diagnosis and treatment. According to the Population Reference Bureau, the number of individuals aged 65 and older in the U.S. was 58 million in 2022 and is projected to rise to 82 million by 2050, a 47% increase. This demographic shift suggests a continued rise in respiratory healthcare needs in the coming years.
   
• Additionally, the availability of health insurance coverage and government reimbursement programs enhances access to respiratory treatments for emphysema patients. For example, the Centers for Medicare & Medicaid Services (CMS) reported that in 2023, Medicare Part B covered a significant portion of the approved amount for respiratory medical equipment and supplies, including homecare oxygen concentrators and nebulizers. These expanded coverage frameworks are improving treatment accessibility and health outcomes for emphysema patients in the U.S.
   

The emphysema treatment market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• Smoking remains a major public health issue in the UK. According to Action on Smoking and Health, 11.9% of adults were smokers in 2023, totaling approximately 6 million adult cigarette smokers. This large population requires medical support for smoking-related illnesses, such as emphysema, driving market growth in the region.
   
• Furthermore, the UK's aging population has contributed to an increase in chronic respiratory diseases, particularly emphysema. The European Respiratory Society reports that around 585,000 new cases of respiratory diseases are diagnosed each year in the UK, highlighting the growing demand for effective treatments for conditions like emphysema.
   

Japan emphysema treatment market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The aging population in Japan is contributing to a higher prevalence of chronic respiratory diseases, including emphysema, which is increasing the demand for treatment options.
   
• According to the World Health Organization (WHO), in 2023, the average life expectancy in Japan was 87.14 years for women and 81.09 years for men, placing Japan among the highest globally.
   
• Additionally, the BBC reports that Japan's rapidly aging population, with 29.1% of citizens aged 65 or older in 2023, is expected to continue driving the growth of the emphysema market in the country.
   

The emphysema treatment market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The National Institutes of Health reported that in 2021, smoking prevalence was higher among men at 25.34%, compared to 1.91% among women in Saudi Arabia. This high smoking rate has led to an increased incidence of emphysema and chronic respiratory diseases, as tobacco smoking is a primary risk factor for these conditions.
   
• Additionally, the Saudi Ministry of Health indicates that respiratory diseases are among the leading causes of mortality in the country, creating a sustained demand for respiratory disease treatments and management solutions.
   

Emphysema Treatment Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. A key strategy for participants is investing in the development of advanced emphysema treatments, such as targeted biologic therapies, long-acting bronchodilators, and combination inhalers, to enhance treatment efficiency. Strategic partnerships with research institutions and healthcare providers are crucial for integrating modern technologies and expanding distribution, enabling companies to address the rising demand for non-invasive and cost-effective diagnostic solutions. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

Emphysema Treatment Industry News:

• In March 2024, AstraZeneca announced the launch of a phase III trial examining Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), a triple-combination inhaled therapy. The trial aimed to evaluate the therapy's effects on severe cardiopulmonary outcomes, including mortality, in COPD patients with high cardiopulmonary risk, regardless of their previous exacerbation history. This development strengthens AstraZeneca's position in the market.
   
• In September 2024, Glaxosmithkline announced positive headline results from the MATINEE phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with COPD. The trial recruited COPD patients with diverse clinical presentations of chronic bronchitis and/or emphysema who were receiving optimized inhaled maintenance therapy. The successful outcomes of this trial provided GSK with a significant opportunity to enhance its portfolio in emphysema treatments.
   

Emphysema Treatment Market Companies

Some of the eminent market participants operating in the emphysema treatment industry include:

• Abbott Laboratories
• AstraZeneca
• Baxter International
• Boehringer Ingelheim
• Boston Scientific Corporation
• Chiesi Farmaceutici
• GlaxoSmithKline
• Grifols
• Koninklijke Philips
• Medtronic
• Novartis
• Olympus Corporation
• Pulmonx Corporation
• ResMed
• Teleflex
   

The emphysema treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medications
  • Bronchodilators
  • Steroids
  • Other medications
• Surgical interventions
  • Lung volume reduction surgery (LVRS)
  • Bullectomy
  • Lung transplantation
• Oxygen therapy

Market, By Type

• Centriacinar
• Panacinar
• Paraseptal

Market, By End Use

• Hospitals
• Specialty clinics
• Ambulatory surgical centers
• Home care settings

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE